PURPOSE: In Radiation Therapy Oncology Group 9704, as previously published, patients with resected pancreatic adenocarcinoma receivedcontinuous infusion 5-FU and concurrent radiotherapy (5FU-RT). 5FU-RT treatment was preceded and followed by randomly assigned chemotherapy, either 5-FU or gemcitabine. This analysis explored whether failure to adhere to specified RT guidelines influenced survival and/or toxicity. METHODS AND MATERIALS: RT requirements were protocol specified. Adherence was scored as per protocol (PP) or less than per protocol (<PP). Scoring occurred after therapy but before trial analysis and without knowledge of individual patient treatment outcomes. Scoring was done for all tumor locations and for the subset of pancreatic head location. RESULTS: RT was scored for 416 patients: 216 PP and 200 <PP. For all pancreatic sites (head, body/tail) median survival (MS) for PP vs. <PP was 1.74 vs. 1.46 years (log-rank p = 0.0077). In multivariate analysis, PP vs. <PP score correlated more strongly with MS than assigned treatment arm (p = 0.014, p = NS, respectively); for patients with pancreatic head tumors, both PP score and gemcitabine treatment correlated with improved MS (p = 0.016, p = 0.043, respectively). For all tumor locations, PP score was associated with decreased risk of failure (p = 0.016) and, for gemcitabine patients, a trend toward reduced Grade 4/5 nonhematologic toxicity (p = 0.065). CONCLUSIONS: This is the first Phase III, multicenter, adjuvant protocol for pancreatic adenocarcinoma to evaluate the impact of adherence to specified RT protocol guidelines on protocol outcomes. Failure to adhere to specified RT guidelines was associated with reduced survival and, for patients receiving gemcitabine, trend toward increased nonhematologic toxicity.
RCT Entities:
PURPOSE: In Radiation Therapy Oncology Group 9704, as previously published, patients with resected pancreatic adenocarcinoma received continuous infusion 5-FU and concurrent radiotherapy (5FU-RT). 5FU-RT treatment was preceded and followed by randomly assigned chemotherapy, either 5-FU or gemcitabine. This analysis explored whether failure to adhere to specified RT guidelines influenced survival and/or toxicity. METHODS AND MATERIALS: RT requirements were protocol specified. Adherence was scored as per protocol (PP) or less than per protocol (<PP). Scoring occurred after therapy but before trial analysis and without knowledge of individual patient treatment outcomes. Scoring was done for all tumor locations and for the subset of pancreatic head location. RESULTS: RT was scored for 416 patients: 216 PP and 200 <PP. For all pancreatic sites (head, body/tail) median survival (MS) for PP vs. <PP was 1.74 vs. 1.46 years (log-rank p = 0.0077). In multivariate analysis, PP vs. <PP score correlated more strongly with MS than assigned treatment arm (p = 0.014, p = NS, respectively); for patients with pancreatic head tumors, both PP score and gemcitabine treatment correlated with improved MS (p = 0.016, p = 0.043, respectively). For all tumor locations, PP score was associated with decreased risk of failure (p = 0.016) and, for gemcitabinepatients, a trend toward reduced Grade 4/5 nonhematologic toxicity (p = 0.065). CONCLUSIONS: This is the first Phase III, multicenter, adjuvant protocol for pancreatic adenocarcinoma to evaluate the impact of adherence to specified RT protocol guidelines on protocol outcomes. Failure to adhere to specified RT guidelines was associated with reduced survival and, for patients receiving gemcitabine, trend toward increased nonhematologic toxicity.
Authors: J P Pignon; R Arriagada; D C Ihde; D H Johnson; M C Perry; R L Souhami; O Brodin; R A Joss; M S Kies; B Lebeau Journal: N Engl J Med Date: 1992-12-03 Impact factor: 91.245
Authors: C J Yeo; R A Abrams; L B Grochow; T A Sohn; S E Ord; R H Hruban; M L Zahurak; W C Dooley; J Coleman; P K Sauter; H A Pitt; K D Lillemoe; J L Cameron Journal: Ann Surg Date: 1997-05 Impact factor: 12.969
Authors: M C Perry; W L Eaton; K J Propert; J H Ware; B Zimmer; A P Chahinian; A Skarin; R W Carey; H Kreisman; C Faulkner Journal: N Engl J Med Date: 1987-04-09 Impact factor: 91.245
Authors: M Overgaard; M B Jensen; J Overgaard; P S Hansen; C Rose; M Andersson; C Kamby; M Kjaer; C C Gadeberg; B B Rasmussen; M Blichert-Toft; H T Mouridsen Journal: Lancet Date: 1999-05-15 Impact factor: 79.321
Authors: M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler Journal: N Engl J Med Date: 1997-10-02 Impact factor: 91.245
Authors: M J O'Connell; J A Martenson; H S Wieand; J E Krook; J S Macdonald; D G Haller; R J Mayer; L L Gunderson; T A Rich Journal: N Engl J Med Date: 1994-08-25 Impact factor: 91.245
Authors: T P Miller; S Dahlberg; J R Cassady; D J Adelstein; C M Spier; T M Grogan; M LeBlanc; S Carlin; E Chase; R I Fisher Journal: N Engl J Med Date: 1998-07-02 Impact factor: 91.245
Authors: John P Neoptolemos; Deborah D Stocken; Helmut Friess; Claudio Bassi; Janet A Dunn; Helen Hickey; Hans Beger; Laureano Fernandez-Cruz; Christos Dervenis; François Lacaine; Massimo Falconi; Paolo Pederzoli; Akos Pap; David Spooner; David J Kerr; Markus W Büchler Journal: N Engl J Med Date: 2004-03-18 Impact factor: 91.245
Authors: Erin E Burke; Schelomo Marmor; Pamela R Portschy; Beth A Virnig; Lawrence C Cho; Todd M Tuttle; Eric H Jensen Journal: HPB (Oxford) Date: 2015-02-28 Impact factor: 3.647
Authors: Kevin L Moore; Rachel Schmidt; Vitali Moiseenko; Lindsey A Olsen; Jun Tan; Ying Xiao; James Galvin; Stephanie Pugh; Michael J Seider; Adam P Dicker; Walter Bosch; Jeff Michalski; Sasa Mutic Journal: Int J Radiat Oncol Biol Phys Date: 2015-04-03 Impact factor: 7.038
Authors: Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad Journal: Ann Surg Oncol Date: 2013-02-23 Impact factor: 5.344
Authors: Nitin Ohri; Xinglei Shen; Adam P Dicker; Laura A Doyle; Amy S Harrison; Timothy N Showalter Journal: J Natl Cancer Inst Date: 2013-03-06 Impact factor: 13.506
Authors: S Gwynne; E Spezi; D Sebag-Montefiore; S Mukherjee; E Miles; J Conibear; J Staffurth Journal: Br J Radiol Date: 2013-02-07 Impact factor: 3.039
Authors: Christos Melidis; Walter R Bosch; Joanna Izewska; Elena Fidarova; Eduardo Zubizarreta; Satoshi Ishikura; David Followill; James Galvin; Ying Xiao; Martin A Ebert; Tomas Kron; Catharine H Clark; Elizabeth A Miles; Edwin G A Aird; Damien C Weber; Kenneth Ulin; Dirk Verellen; Coen W Hurkmans Journal: Radiother Oncol Date: 2014-05-08 Impact factor: 6.280
Authors: Richard Y Lee; Romaine C Nichols; Soon N Huh; Meng W Ho; Zuofeng Li; Robert Zaiden; Ziad T Awad; Bestoun Ahmed; Bradfors S Hoppe Journal: J Gastrointest Oncol Date: 2013-12